Trial · NCT07008638
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
NCT07008638, Phase 1, Phase 2, Recruiting, Masonic Cancer Center, University of Minnesota
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML). Trials, record NCT07008638. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07008638
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- NCT number
- NCT07008638
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 32 participants, estimated
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Acute Myeloid Leukemia, TP53
- Interventions
- Bortezomib, CPX-351
- First posted
- 2025-06-06
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants with Complete Response | 2 years | To evaluate the CR rate of bortezomib + CPX-351 for the treatment of TP53m AML. |
| Primary | Determine Maximum Tolerated Dose | 1 year | |
| Secondary | Determine Overall Response Rate | 2 years | Evaluate ORR (CR+CRi) after treatment |
| Secondary | Average rate of allo-HCT among participants | 2 years | Evaluate the rate of allo-HCT within 2 years among patients who received treatment |
| Secondary | Overall Survival | 1 year | estimate 1-year and 2-year OS, defined as the time from cohort assignment to death from any cause |
| Secondary | Overall Survival | 2 year | estimate 1-year and 2-year OS, defined as the time from cohort assignment to death from any cause |
| Secondary | Average time to relapse | 2 year | • To estimate time to relapse, defined as the time from cohort assignment to disease recurrence |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07008638
GET https://conductscience.org/api/trials/v1/NCT07008638/registered